Deutsche Bank AG Cuts Position in Illumina, Inc. (NASDAQ:ILMN)

Deutsche Bank AG lessened its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 418,184 shares of the life sciences company's stock after selling 59,764 shares during the period. Deutsche Bank AG owned about 0.26% of Illumina worth $33,179,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Freedom Investment Management Inc. lifted its stake in shares of Illumina by 3.7% in the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock worth $382,000 after buying an additional 101 shares in the last quarter. Moors & Cabot Inc. lifted its stake in Illumina by 2.5% in the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock worth $465,000 after acquiring an additional 145 shares during the last quarter. Probity Advisors Inc. lifted its position in shares of Illumina by 12.2% during the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after buying an additional 224 shares during the last quarter. Xponance Inc. raised its position in Illumina by 1.0% in the 1st quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock valued at $2,123,000 after purchasing an additional 264 shares during the last quarter. Finally, Rakuten Securities Inc. increased its stake in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after buying an additional 270 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ILMN shares. Barclays boosted their price objective on shares of Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a research report on Friday, August 1st. Evercore ISI upped their target price on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Stephens set a $110.00 price objective on shares of Illumina and gave the stock an "overweight" rating in a report on Monday, August 4th. Canaccord Genuity Group increased their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a report on Friday, August 1st. Finally, Daiwa Capital Markets downgraded shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price for the company. in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $124.58.

Illumina Price Performance

Shares of Illumina stock traded up $0.02 during trading on Friday, reaching $100.11. 1,534,729 shares of the stock traded hands, compared to its average volume of 2,192,190. The business has a fifty day simple moving average of $96.81 and a two-hundred day simple moving average of $90.15. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a market capitalization of $15.39 billion, a price-to-earnings ratio of 12.67, a P/E/G ratio of 2.25 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. Illumina's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.36 earnings per share. Sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.